Research Radartracking 1,189 published studies · 293 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curateddacarbazine
Educational only, not medical advice. OncoForge makes no claim that Dacarbazine treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
This narrative review summarizes evidence-based management of recurrent and metastatic uterine leiomyosarcoma. For disseminated disease the authors state fixed‑dose‑rate gemcitabine plus docetaxel is an appropriate first-line chemotherapy and list other active cytotoxic agents (doxorubicin, ifosfamide, dacarbazine). They note trabectedin and other targeted therapies are under investigation (pazopanib is currently the only approved targeted therapy for advanced soft tissue sarcoma) and that aromatase inhibitors may be reasonable for small-volume, slowly progressive ER/PR-positive disease. The authors conclude overall survival for advanced disease remains poor and novel agents are needed.
Studied with: fixed-dose-rate gemcitabine plus docetaxel.
Key findings
Selected patients with localized or single-organ oligometastatic disease may benefit from surgical resection.
For patients with disseminated disease, fixed-dose-rate gemcitabine plus docetaxel is an appropriate first-line chemotherapy regimen.
Other active cytotoxic agents include doxorubicin, ifosfamide, and dacarbazine.
The role of trabectedin is being explored; trabectedin is approved by the European Medicine Agency to be marketed for advanced or metastatic soft tissue sarcoma.
Trials are underway for targeted therapy in uterine LMS; currently, the only approved targeted therapy for advanced soft tissue sarcoma is pazopanib.
In patients with small volume and slowly progressive estrogen receptor/progesterone receptor-positive disease, antiestrogen therapy with an aromatase inhibitor is a reasonable alternative to observation alone.
Despite recent advances, overall survival for advanced disease remains poor and identification of novel agents with activity in LMS is needed.
Limitations: Narrative review rather than primary data or systematic review; no new quantitative results presented in this article.; Conclusions depend on the quantity and quality of existing trials, which are not detailed in the abstract.; No sample sizes, effect sizes, or trial-level data are reported in the abstract to support comparative effectiveness claims..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
The Cochrane database of systematic reviews · Feb 2013 · Cochrane systematic review of randomized controlled trials (searched for RCTs) and discussion of non-randomised studies; search up to February 2012
This Cochrane systematic review searched for randomized trials comparing neoadjuvant or adjuvant chemotherapy and radiotherapy, or chemotherapy alone, combined with surgery for ovarian carcinosarcoma and found no eligible randomized controlled trials. The authors therefore found no evidence to inform decisions about which adjuvant or neoadjuvant regimens to use and called for multicentre RCTs or well-designed non-randomised studies and further molecular research.
No randomized controlled trials were identified comparing neoadjuvant or adjuvant chemotherapy and radiotherapy, or chemotherapy alone, in women with ovarian carcinosarcoma.
The search strategy identified 297 unique references, all of which were excluded and therefore no data were analysed.
Various chemotherapy regimens have been used historically (including cisplatin; combinations with doxorubicin, ifosfamide, dacarbazine, cyclophosphamide, taxol), but their effectiveness appears mixed.
Authors recommend multicentre or multinational RCTs, or well-designed non-randomised studies using multivariate analysis, and further research into genetic and molecular signalling pathways.
The authors note the importance of addressing quality of life and toxicity given the generally poor prognosis.
Limitations: No randomized controlled trials were found, so no quantitative data or pooled analysis could be performed.; Search was conducted up to February 2012; more recent studies (after that date) would not be included.; Rare disease with likely limited available studies, limiting the ability to draw conclusions..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Dacarbazine's evidence base, and anything that's been retracted.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Dacarbazine depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
0 ongoing · 4 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.